Plain language summary of the iNNOVATE study: Ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia Review
| Authors: | Buske, C.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Matous, J. V.; Tam, C. S.; Heffner, L T.; Varettoni, M; Palomba, M. L.; Shustik, C.; Kastritis, E.; Treon, S. P.; Ping, J.; Hauns, B.; Arango-Hisijara, I.; Dimopoulos, M. A. |
| Review Title: | Plain language summary of the iNNOVATE study: Ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia |
| Journal Title: | Future Oncology |
| Volume: | 19 |
| Issue: | 5 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2023-02-01 |
| Start Page: | 345 |
| End Page: | 353 |
| Language: | English |
| DOI: | 10.2217/fon-2022-1015 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 36815271 |
| DOI/URL: | |
| Notes: | Accession Number: 163315677 -- Entry Date: In Process -- Revision Date: 20230427 -- Publication Type: Article -- Journal Subset: Biomedical; Europe; UK & Ireland -- NLM UID: 101256629. -- Source: Cinahl |
